Ruxolitinib in Severe, COVID-19 Patients: A Randomized Phase-II Trial

Sep 2, 2020

A prospective, multi-center, single-blind, randomized controlled phase II trial assessing the efficacy and safety of ruxolitinib in hospitalized COVID-19 patients